VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

NCT06447090 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Relapse Acute Myeloid Leukemia

Interventions

DRUG: Mitoxantrone hydrochloride liposome

Sponsor

Institute of Hematology & Blood Diseases Hospital, China